Stay updated on Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial
Sign up to get notified when there's something new on the Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial page.

Latest updates to the Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision tag updated from v3.5.2 to v3.5.3, representing a minor version update to the page.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe page revision label was updated to Revision: v3.5.2, replacing the previous Revision: v3.5.0.SummaryDifference0.1%

- Check57 days agoChange DetectedAdded revision: v3.5.0; deleted revision: v3.4.3.SummaryDifference0.1%

- Check64 days agoChange DetectedAdded Revision: v3.4.3 and removed Revision: v3.4.2 to reflect the page's latest version.SummaryDifference0.1%

- Check92 days agoChange DetectedRevision: v3.4.2 has been added, and the funding-lapse notice has been removed. This update does not modify study content, eligibility criteria, or outcomes.SummaryDifference0.4%

- Check99 days agoChange DetectedThe page now shows a government funding notice regarding potential delays and open status of the NIH Clinical Center, and the site revision was updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

Stay in the know with updates to Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial page.